Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C, Paisie C, Lovat F, Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K. Gasparini P, et al. Among authors: cascione l. PLoS One. 2014 Feb 5;9(2):e88525. doi: 10.1371/journal.pone.0088525. eCollection 2014. PLoS One. 2014. PMID: 24505496 Free PMC article.
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Johnson Z, Tarantelli C, Civanelli E, Cascione L, Spriano F, Fraser A, Shah P, Nomanbhoy T, Napoli S, Rinaldi A, Niewola-Staszkowska K, Lahn M, Perrin D, Wenes M, Migliorini D, Bertoni F, van der Veen L, Di Conza G. Johnson Z, et al. Among authors: cascione l. Cancer Res Commun. 2023 Apr 14;3(4):576-591. doi: 10.1158/2767-9764.CRC-22-0477. eCollection 2023 Apr. Cancer Res Commun. 2023. PMID: 37066023 Free PMC article.
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, Bertoni F. Sartori G, et al. Among authors: cascione l. Br J Haematol. 2024 Jan;204(1):191-205. doi: 10.1111/bjh.19218. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38011941
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, Castro de Moura M, Jovic S, Bordone Pittau R, Stathis A, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F. Arribas AJ, et al. Among authors: cascione l. Mol Cancer Ther. 2024 Mar 4;23(3):368-380. doi: 10.1158/1535-7163.MCT-23-0068. Mol Cancer Ther. 2024. PMID: 38052765
ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.
Chung EYL, Sartori G, Ponzoni M, Cascione L, Priebe V, Xu-Monette ZY, Fang X, Zhang M, Visco C, Tzankov A, Rinaldi A, Sgrignani J, Zucca E, Rossi D, Cavalli A, Inghirami G, Scott DW, Young KH, Bertoni F. Chung EYL, et al. Among authors: cascione l. Br J Haematol. 2023 Oct;203(2):244-254. doi: 10.1111/bjh.19018. Epub 2023 Aug 16. Br J Haematol. 2023. PMID: 37584198
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, de Moura MC, Jovic S, Pittau RB, Stathis A, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F. Arribas AJ, et al. Among authors: cascione l. bioRxiv [Preprint]. 2023 Jan 2:2023.01.01.522017. doi: 10.1101/2023.01.01.522017. bioRxiv. 2023. Update in: Mol Cancer Ther. 2024 Mar 4;23(3):368-380. doi: 10.1158/1535-7163.MCT-23-0068 PMID: 36711490 Free PMC article. Updated. Preprint.
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. Garofalo M, et al. Among authors: cascione l. Nat Med. 2011 Dec 11;18(1):74-82. doi: 10.1038/nm.2577. Nat Med. 2011. Retraction in: Nat Med. 2022 Nov;28(11):2436. doi: 10.1038/s41591-022-02044-2 PMID: 22157681 Free PMC article. Retracted.
Regulation of acute graft-versus-host disease by microRNA-155.
Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R. Ranganathan P, et al. Among authors: cascione l. Blood. 2012 May 17;119(20):4786-97. doi: 10.1182/blood-2011-10-387522. Epub 2012 Mar 9. Blood. 2012. PMID: 22408260 Free PMC article.
131 results